Lucchetta RC, et al. - Considering the uncertainty regarding the efficacy and safety of traditional disease-modifying therapies (DMTs) vs recently developed DMTs in adults with relapsing–remitting multiple sclerosis (RRMS), researchers analyzed the available evidence of clinical outcomes for DMTs. They identified high-quality evidence which showed the highest efficacy among DMTs was seen in alemtuzumab, natalizumab and ocrelizumab. Across all therapies, discontinuation due to adverse events was similar, except for alemtuzumab, which showed less discontinuation when compared with interferon-1a intramuscular. A three-category classification, based on efficacy profile (ie, high, intermediate and low efficacy), should be considered in guidelines.